Xiang-Guo Li
Associate Professor
Turku PET Centre, University of Turku xiali@utu.fi Kiinamyllynkatu 10 Turku : https://orcid.org/0000-0002-9118-7223 |
Radiochemistry, Radiopharmaceuticals, PET imaging, New drug development
Radiochemistry, Radiopharmaceuticals, InFLAMES Flagship
I am a radiochemist and medicinal chemist working at Turku PET Centre, University of Turku, Finland. I received my PhD degree from the Institute of Biomedicine, Faculty of Medicine, University of Turku, in 2008. Then I was at a Post-doctoral position funded by the Academy of Finland during 2010-2012. I received my Docentship in 2012 from University of Turku. Since 2013, I have been working at Turku PET Centre. At present, I work as an Assistant Professor in Radiochemistry, and Principal Investigator in the InFLAMES Research Flagship.
Basic research in radiochemistry including methodological development for radiosynthesis and radiolabeling techniques. We have been able to radiolabel many types of molecules including small organic compounds, peptides, antibody and antibody fragments, oligonucleotides, oligosaccharides etc.
Development of new radiopharmaceuticals for PET imaging of inflammatory diseases and immunological diseases.
The radiolabeled molecules are for imaging diseases or for studying disease machanisms with PET.
I teach in the courses of Radiopharmaceutical Chemistry, Radiolabeling techniques, Measuring techniques in radiochemistry, PET Basics, and supervise BSc, MSc and PhD students.
- Evaluation of a clinically efficient [18F]FDG PET/CT protocol: short dynamic and two-phase static imaging for differentiating malignant pulmonary lesions (2026)
- EJNMMI Research
- Exclusively chemoselective S-acylation for peptide radiolabeling using [18F]fluoronicotinic acid 4-nitrophenyl ester as a prosthetic compound (2026)
- ACS Omega
- Folate receptor β-targeted Positron emission tomography imaging of activated macrophages in experimental myocardial infarctionRapid cleavage of 6-[18F]fluoronicotinic acid prosthetic group governs BT12 glioblastoma xenograft uptake: implications for radiolabeling design of biomolecules2026
- Journal of Nuclear CardiologyEJNMMI Radiopharmacy and Chemistry
- Intracranial Human BT12 Glioblastoma Xenograft is [18F]FET PET Negative but 6-[18F]Fluoronicotinic Acid PET Positive: Exploring a Novel Approach for Clinical Glioblastoma Imaging (2026)
- Molecular PharmaceuticsACS Omega
- [18F]Fluoronicotinic-Acid-Conjugated Folate as a Novel Candidate Positron Emission Tomography Tracer for Inflammation (2025)
- Comparing Two Folate Receptor β-Targeted Tracers in a Rat Model of Experimental Autoimmune Myocarditis (2025)
- ACS pharmacology & translational scienceEJNMMI Radiopharmacy and Chemistry
- Highlight selection of radiochemistry and radiopharmacy developments by editorial board (2025)
- Longitudinal monitoring of nanofibrillar cellulose hydrogel medical implants in mice using positron emission tomography (2025)
- European Journal of Pharmaceutical Sciences
- Macrophage mannose receptor CD206-targeted PET imaging in experimental acute myocardial infarction (2025)
- EJNMMI Research
- (2025)



